Abliva AB (publ) (NEVPF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -35.66 Million SEK | 56.59% |
| 2022 | -8.1 Million USD | -127.6% |
| 2021 | -3.56 Million USD | 9.16% |
| 2020 | -3.92 Million USD | -16.71% |
| 2019 | -3.36 Million USD | 8.54% |
| 2018 | -3.67 Million SEK | 7.36% |
| 2017 | -3.96 Million SEK | 6.53% |
| 2016 | -4.24 Million SEK | 29.03% |
| 2015 | -5.97 Million SEK | -434.21% |
| 2014 | 1.78 Million SEK | -3.41% |
| 2013 | 1.85 Million SEK | 0.0% |
| 2012 | - SEK | -100.0% |
| 2011 | 5.55 Million SEK | 60.91% |
| 2010 | 3.45 Million SEK | -22.11% |
| 2009 | 4.43 Million SEK | 387.83% |
| 2008 | 908.66 Thousand SEK | 0.0% |
| 2007 | - SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -46.01 Thousand USD | -1.03% |
| 2024 Q1 | -45.29 Thousand USD | 93.95% |
| 2023 FY | -3.51 Million USD | 56.59% |
| 2023 Q2 | -65.9 Thousand USD | 3.35% |
| 2023 Q3 | -777.02 Thousand USD | -1079.06% |
| 2023 Q4 | -790.88 Thousand USD | -1.78% |
| 2023 Q1 | -68.18 Thousand USD | -2.0% |
| 2022 Q2 | -739.26 Thousand SEK | -1044.92% |
| 2022 Q3 | -608.61 Thousand USD | 17.67% |
| 2022 Q4 | -66.85 Thousand USD | 89.02% |
| 2022 FY | -8.1 Million USD | -127.6% |
| 2022 Q1 | -64.56 Thousand SEK | 98.41% |
| 2021 Q3 | -1.29 Million SEK | -15.74% |
| 2021 Q4 | -4.07 Million SEK | -215.63% |
| 2021 Q1 | -75.49 Thousand SEK | 94.11% |
| 2021 Q2 | -1.11 Million SEK | -1377.07% |
| 2021 FY | -3.56 Million USD | 9.16% |
| 2020 Q3 | -747.62 Thousand SEK | 53.5% |
| 2020 Q4 | -1.28 Million SEK | -71.58% |
| 2020 FY | -3.92 Million USD | -16.71% |
| 2020 Q1 | -1.2 Million SEK | 51.12% |
| 2020 Q2 | -1.6 Million SEK | -33.93% |
| 2019 Q2 | -1.73 Million SEK | -67.98% |
| 2019 FY | -3.36 Million USD | 8.54% |
| 2019 Q1 | -1.03 Million SEK | 35.93% |
| 2019 Q3 | -1.17 Million SEK | 32.31% |
| 2019 Q4 | -2.45 Million SEK | -108.54% |
| 2018 Q1 | -1.08 Million SEK | 24.89% |
| 2018 Q2 | -2.2 Million SEK | -103.06% |
| 2018 Q3 | -1.26 Million SEK | 42.68% |
| 2018 Q4 | -1.61 Million SEK | -28.12% |
| 2018 FY | -3.67 Million SEK | 7.36% |
| 2017 Q4 | -1.44 Million SEK | -20.5% |
| 2017 Q3 | -1.19 Million SEK | 44.16% |
| 2017 Q2 | -2.14 Million SEK | -196.13% |
| 2017 Q1 | -724.46 Thousand SEK | 32.2% |
| 2017 FY | -3.96 Million SEK | 6.53% |
| 2016 Q2 | -915.18 Thousand SEK | -0.49% |
| 2016 Q1 | -910.72 Thousand SEK | -100.1% |
| 2016 Q3 | -1.06 Million SEK | -16.82% |
| 2016 FY | -4.24 Million SEK | 29.03% |
| 2016 Q4 | -1.06 Million SEK | 0.05% |
| 2015 Q1 | - SEK | 100.0% |
| 2015 Q3 | -2.34 Million SEK | -397.83% |
| 2015 Q4 | -455.12 Thousand SEK | 80.6% |
| 2015 Q2 | 787.84 Thousand SEK | 0.0% |
| 2015 FY | -5.97 Million SEK | -434.21% |
| 2014 Q4 | -1.61 Million SEK | -126.78% |
| 2014 FY | 1.78 Million SEK | -3.41% |
| 2014 Q1 | - SEK | 100.0% |
| 2014 Q2 | -1.84 Million SEK | 0.0% |
| 2014 Q3 | 6.02 Million SEK | 426.18% |
| 2013 Q1 | 107.82 Thousand SEK | 0.0% |
| 2013 FY | 1.85 Million SEK | 0.0% |
| 2013 Q4 | -1.04 Million SEK | -27.41% |
| 2013 Q3 | -818.23 Thousand SEK | -118.22% |
| 2013 Q2 | 4.49 Million SEK | 4064.63% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | -100.0% |
| 2012 FY | - SEK | -100.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2011 Q4 | 556.46 Thousand SEK | -36.02% |
| 2011 FY | 5.55 Million SEK | 60.91% |
| 2011 Q2 | 2.7 Million SEK | 88.88% |
| 2011 Q1 | 1.42 Million SEK | 54.04% |
| 2011 Q3 | 869.8 Thousand SEK | -67.79% |
| 2010 Q1 | 386.45 Thousand SEK | -76.7% |
| 2010 FY | 3.45 Million SEK | -22.11% |
| 2010 Q3 | 1.7 Million SEK | 290.86% |
| 2010 Q2 | 435.62 Thousand SEK | 12.72% |
| 2010 Q4 | 928.01 Thousand SEK | -45.5% |
| 2009 FY | 4.43 Million SEK | 387.83% |
| 2009 Q2 | 909.98 Thousand SEK | 38.74% |
| 2009 Q1 | 655.9 Thousand SEK | 0.0% |
| 2009 Q3 | 1.2 Million SEK | 32.75% |
| 2009 Q4 | 1.65 Million SEK | 37.31% |
| 2008 FY | 908.66 Thousand SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 337.769% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | 1149777.627% |
| SQZ Biotechnologies Company | 9.79 Million USD | 464.131% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 404.656% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 129.942% |
| Mesoblast Limited | -35.16 Million USD | -1.408% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | -104330.454% |
| Genus plc | 178.7 Million USD | 119.957% |
| VioQuest Pharmaceuticals, Inc. | - USD | Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 8794.794% |
| Marizyme, Inc. | 457.7 Thousand USD | 7891.751% |
| ContraFect Corporation | -154 Thousand USD | -23057.792% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | -324109.091% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | -71226.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | 46559.791% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | 54358.459% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | -9103.331% |
| MultiCell Technologies, Inc. | 49.32 USD | 72309507.948% |
| Accustem Sciences Inc. | - USD | Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 188.571% |
| EV Biologics, Inc. | 48.9 Thousand USD | 73030.47% |
| Q BioMed Inc. | -8988.00 USD | -396684.602% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 226.218% |
| Neon Bloom, Inc. | - USD | Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | -231117.583% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 116.203% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | 51047.143% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | -28602.385% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | 57412.056% |
| THC Farmaceuticals, Inc. | -4952.00 USD | -720073.667% |
| Arch Therapeutics, Inc. | -2439.00 USD | -1462097.622% |
| IMV Inc. | -962.29 Thousand USD | -3606.025% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 25482.918% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | -36471.809% |
| GB Sciences, Inc. | -624.00 USD | -5715124.359% |
| Alpha Cognition Inc. | -86.02 Thousand USD | -41355.108% |
| HST Global, Inc. | - USD | Infinity% |
| CSL Limited | 7.56 Billion USD | 100.472% |
| Halberd Corporation | -208.00 USD | -17145573.077% |
| Enzolytics Inc. | 30.7 Thousand USD | 116235.86% |
| Resverlogix Corp. | - USD | Infinity% |
| Affymax, Inc. | 1.35 Million USD | 2727.8% |
| SYBLEU INC | 11.69 Thousand USD | 305016.211% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 7492.322% |
| argenx SE | 1.1 Billion USD | 103.217% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | -38.239% |
| Enzon Pharmaceuticals, Inc. | - USD | Infinity% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | Infinity% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 5876.47% |
| Zenith Capital Corp. | - USD | Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 108.708% |
| Ember Therapeutics, Inc. | - USD | Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | -402598.735% |
| WPD Pharmaceuticals Inc. | - USD | Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 180.398% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | -3024.025% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 3709.685% |
| GlobeStar Therapeutics Corporation | - USD | Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 471.064% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | -42432.409% |
| BioStem Technologies, Inc. | 15.42 Million USD | 331.205% |
| ONE Bio Corp. | 20.12 Million USD | 277.204% |
| Reve Technologies, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | - USD | Infinity% |
| Agentix Corp. | - USD | Infinity% |
| LadRx Corporation | -11.83 Thousand USD | -301235.023% |
| Cell Source, Inc. | - USD | Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | -73799.169% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 20298.799% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 20298.799% |
| NovAccess Global Inc. | - USD | Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | -6831.449% |
| Itoco Inc. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | - USD | Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -630.13 Thousand USD | -5559.554% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | - USD | Infinity% |
| CytoDyn Inc. | -29 Thousand USD | -122875.862% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | - USD | Infinity% |
| Mobile Lads Corp. | - USD | Infinity% |
| NanoSphere Health Sciences Inc. | - USD | Infinity% |
| Qrons Inc. | - USD | Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 8024.354% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | -11061.884% |
| Rebus Holdings, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 873.937% |
| Bioxytran, Inc. | -8285.00 USD | -430352.625% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | - USD | Infinity% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | - USD | Infinity% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | - USD | Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | -9461.126% |
| Neutra Corp. | 14.33 Thousand USD | 248882.7% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | -43391.463% |
| PureTech Health plc | -1.6 Million USD | -2124.766% |
| Coeptis Therapeutics, Inc. | -1 Million USD | -3461.897% |
| IXICO plc | 3.27 Million USD | 1190.612% |
| IntelGenx Technologies Corp. | -694 Thousand USD | -5038.761% |
| Gelesis Holdings, Inc. | -1.79 Million USD | -1891.234% |
| CSL Limited | 7.7 Billion USD | 100.463% |
| Cellectis S.A. | 18 Thousand USD | 198227.778% |